(Q39384559)

11 September 2017

CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway (English)

1 reference

11 September 2017

1 reference

4

1 reference

11 September 2017

Daniel Sinnett

10

0 references

author name string

Hervé Sartelet

1

1 reference

11 September 2017

Tina Imbriglio

2

1 reference

11 September 2017

Carine Nyalendo

3

1 reference

11 September 2017

Borhane Annabi

5

1 reference

11 September 2017

Michel Duval

6

1 reference

11 September 2017

Raouf Fetni

7

1 reference

11 September 2017

Kokta Victor

8

1 reference

11 September 2017

Lubo Alexendrov

9

1 reference

11 September 2017

Monique Fabre

11

1 reference

11 September 2017

Gilles Vassal

12

1 reference

11 September 2017

language of work or name

1 reference

6 March 2012

1 reference

11 September 2017

1 reference

11 September 2017

60

1 reference

11 September 2017

7

1 reference

11 September 2017

1144-1155

1 reference

CD133: molecule of the moment

11 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

The cancer stem cell hypothesis: a work in progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Long-term outcomes in patients with stage IV neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Long-term outcomes of adult survivors of childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Neuroblastoma Screening at One Year of Age

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Screening of infants and mortality due to neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Expression and clinical significance of stem cell marker CD133 in human neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Human neuroblastoma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

PKB binding proteins. Getting in on the Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

The protein kinase B/Akt signalling pathway in human malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Akt signaling and cancer: surviving but not moving on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Autophosphorylation of Akt at threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

CD133 suppresses neuroblastoma cell differentiation via signal pathway modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

CD133 expression is an independent prognostic marker for low survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Stem cell marker CD133 affects clinical outcome in glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Neuroblastoma: biological insights into a clinical enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Influence of oxygen tension on CD133 phenotype in human glioma cell cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Tumour stem cells and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

Cancer stem cells in human gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04191.X

10.1111/J.1365-2559.2012.04191.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference